Prophylactic colchicine therapy of intercritical gout. A placebo‐controlled study of probenecid‐treated patients

Abstract The serum urate‐lowering effect of probenecid was used to monitor compliance in a placebo‐controlled study of prophylactic colchicine therapy for intercritical gout. Although all patients included in the analysis had satisfactory control of hyperuricemia, 20 patients receiving 1.5 mg of colchicine daily averaged 2.3 attacks of acute gout per year of therapy, compared to 18 placebo‐treated patients who averaged 6 attacks per year (P < 0.05), confirming the effectiveness of prophylactic colchicine in this situation.